Journal article
The cost effectiveness of palivizumab: a systematic review of the evidence
Abstract
OBJECTIVE: Palivizumab is a prophylactic therapy shown to reduce the number of respiratory syncytial virus (RSV)-related hospitalizations but has a high acquisition cost. The objective was to systematically examine the cost effectiveness of palivizumab in defined infant groups and identify important cost and outcome determinants.
METHODS: Literature searches of MedLine, the Cost-Effectiveness Analysis registry and the UK NHS Economic Evaluation …
Authors
Smart KA; Lanctôt KL; Paes BA
Journal
Journal of Medical Economics, Vol. 13, No. 3, pp. 453–463
Publisher
Taylor & Francis
Publication Date
September 2010
DOI
10.3111/13696998.2010.499749
ISSN
1369-6998